Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Mor Research Applications Ltd.

Deutsches Krebsforschungszentrum

Mina Fogel

Peter Altevogt

Daniela Kelm

Described is a pharmaceutical composition comprising a compound(s) interfering with the biological activity of L1 and/or ADAM10 or their expression. Also described is the use of said compound(s) for the prevention/treatment of carcinomas like ovarian and endometrial carcinoma. Finally, the diagnosis of highly malignant forms of carcinomas which is based on the determination of the activity/expression of L1 and/or ADAM10 is described.

Inhibitors of L1 and ADAM10 for the treatment of carcinomas

A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.

Growing community of inventors

Gedera, Israel

Mina Fogel